Logo image of EOLS

EVOLUS INC (EOLS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:EOLS - US30052C1071 - Common Stock

5.91 USD
-0.14 (-2.31%)
Last: 1/6/2026, 8:00:02 PM
5.91 USD
0 (0%)
After Hours: 1/6/2026, 8:00:02 PM
Fundamental Rating

2

EOLS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of EOLS have multiple concerns. While showing a medium growth rate, EOLS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EOLS has reported negative net income.
In the past year EOLS has reported a negative cash flow from operations.
EOLS had negative earnings in each of the past 5 years.
In the past 5 years EOLS always reported negative operating cash flow.
EOLS Yearly Net Income VS EBIT VS OCF VS FCFEOLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

EOLS has a Return On Assets (-26.74%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -26.74%
ROE N/A
ROIC N/A
ROA(3y)-32.04%
ROA(5y)-38.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EOLS Yearly ROA, ROE, ROICEOLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

Looking at the Gross Margin, with a value of 65.83%, EOLS is in the better half of the industry, outperforming 74.87% of the companies in the same industry.
EOLS's Gross Margin has declined in the last couple of years.
EOLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.76%
GM growth 5Y-2.34%
EOLS Yearly Profit, Operating, Gross MarginsEOLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

2

2. Health

2.1 Basic Checks

EOLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EOLS has been increased compared to 1 year ago.
The number of shares outstanding for EOLS has been increased compared to 5 years ago.
The debt/assets ratio for EOLS has been reduced compared to a year ago.
EOLS Yearly Shares OutstandingEOLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
EOLS Yearly Total Debt VS Total AssetsEOLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -2.17, we must say that EOLS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.17, EOLS perfoms like the industry average, outperforming 42.41% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.17
ROIC/WACCN/A
WACC10.92%
EOLS Yearly LT Debt VS Equity VS FCFEOLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

EOLS has a Current Ratio of 2.02. This indicates that EOLS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of EOLS (2.02) is worse than 60.73% of its industry peers.
EOLS has a Quick Ratio of 1.53. This is a normal value and indicates that EOLS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.53, EOLS is doing worse than 61.78% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 1.53
EOLS Yearly Current Assets VS Current LiabilitesEOLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

EOLS shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.76%.
EOLS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.10%.
EOLS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 50.14% yearly.
EPS 1Y (TTM)-9.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.25%
Revenue 1Y (TTM)15.1%
Revenue growth 3Y38.74%
Revenue growth 5Y50.14%
Sales Q2Q%12.9%

3.2 Future

The Earnings Per Share is expected to grow by 67.42% on average over the next years. This is a very strong growth
Based on estimates for the next years, EOLS will show a very strong growth in Revenue. The Revenue will grow by 21.06% on average per year.
EPS Next Y-81.56%
EPS Next 2Y63.87%
EPS Next 3Y72.82%
EPS Next 5Y67.42%
Revenue Next Year12.01%
Revenue Next 2Y16.79%
Revenue Next 3Y21.05%
Revenue Next 5Y21.06%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EOLS Yearly Revenue VS EstimatesEOLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
EOLS Yearly EPS VS EstimatesEOLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EOLS. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 34.49, the valuation of EOLS can be described as expensive.
EOLS's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. EOLS is cheaper than 70.68% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.79, EOLS is valued a bit more expensive.
Industry RankSector Rank
PE N/A
Fwd PE 34.49
EOLS Price Earnings VS Forward Price EarningsEOLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EOLS Per share dataEOLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

A more expensive valuation may be justified as EOLS's earnings are expected to grow with 72.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y63.87%
EPS Next 3Y72.82%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EOLS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

EVOLUS INC

NASDAQ:EOLS (1/6/2026, 8:00:02 PM)

After market: 5.91 0 (0%)

5.91

-0.14 (-2.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-02 2026-03-02/amc
Inst Owners80.28%
Inst Owner Change0%
Ins Owners9.06%
Ins Owner Change0.24%
Market Cap383.09M
Revenue(TTM)285.82M
Net Income(TTM)-58.56M
Analysts84.62
Price Target18.87 (219.29%)
Short Float %11.86%
Short Ratio4.89
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-35.65%
Min EPS beat(2)-108.79%
Max EPS beat(2)37.48%
EPS beat(4)2
Avg EPS beat(4)-17.26%
Min EPS beat(4)-108.79%
Max EPS beat(4)37.48%
EPS beat(8)4
Avg EPS beat(8)-20.62%
EPS beat(12)8
Avg EPS beat(12)-11.91%
EPS beat(16)10
Avg EPS beat(16)-7.81%
Revenue beat(2)1
Avg Revenue beat(2)-8.42%
Min Revenue beat(2)-17.08%
Max Revenue beat(2)0.25%
Revenue beat(4)1
Avg Revenue beat(4)-6.22%
Min Revenue beat(4)-17.08%
Max Revenue beat(4)0.25%
Revenue beat(8)2
Avg Revenue beat(8)-3.54%
Revenue beat(12)5
Avg Revenue beat(12)-1.7%
Revenue beat(16)6
Avg Revenue beat(16)-1.26%
PT rev (1m)-0.89%
PT rev (3m)-4.07%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-42.5%
EPS NY rev (1m)0%
EPS NY rev (3m)7.77%
Revenue NQ rev (1m)-0.47%
Revenue NQ rev (3m)-0.14%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)0.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 34.49
P/S 1.34
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)0.17
Fwd EY2.9%
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS4.41
BVpS-0.44
TBVpS-1.52
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.74%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.83%
FCFM N/A
ROA(3y)-32.04%
ROA(5y)-38.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.76%
GM growth 5Y-2.34%
F-Score2
Asset Turnover1.31
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 124.54%
Cap/Sales 2.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.02
Quick Ratio 1.53
Altman-Z -2.17
F-Score2
WACC10.92%
ROIC/WACCN/A
Cap/Depr(3y)67.26%
Cap/Depr(5y)52.74%
Cap/Sales(3y)1.53%
Cap/Sales(5y)2.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.25%
EPS Next Y-81.56%
EPS Next 2Y63.87%
EPS Next 3Y72.82%
EPS Next 5Y67.42%
Revenue 1Y (TTM)15.1%
Revenue growth 3Y38.74%
Revenue growth 5Y50.14%
Sales Q2Q%12.9%
Revenue Next Year12.01%
Revenue Next 2Y16.79%
Revenue Next 3Y21.05%
Revenue Next 5Y21.06%
EBIT growth 1Y-20.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-616.62%
EBIT Next 3Y288.57%
EBIT Next 5Y217.01%
FCF growth 1Y-25.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.36%
OCF growth 3YN/A
OCF growth 5YN/A

EVOLUS INC / EOLS FAQ

What is the ChartMill fundamental rating of EVOLUS INC (EOLS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to EOLS.


What is the valuation status of EVOLUS INC (EOLS) stock?

ChartMill assigns a valuation rating of 1 / 10 to EVOLUS INC (EOLS). This can be considered as Overvalued.


How profitable is EVOLUS INC (EOLS) stock?

EVOLUS INC (EOLS) has a profitability rating of 1 / 10.


What is the financial health of EVOLUS INC (EOLS) stock?

The financial health rating of EVOLUS INC (EOLS) is 2 / 10.


Can you provide the expected EPS growth for EOLS stock?

The Earnings per Share (EPS) of EVOLUS INC (EOLS) is expected to decline by -81.56% in the next year.